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Abstract Uptake of oxidized low density lipoprotein (Ox-LDL)
and subsequent foam cell transformation have been implicated in
early atherogenesis. Although multiple molecules, including class
A and B scavenger receptors, have been identified as Ox-LDL
receptors, additional receptors may also be involved in this
process. Here, we provide evidence that lectin-like Ox-LDL
receptor-1 (LOX-1), a novel Ox-LDL receptor initially identi-
fied in vascular endothelial cells, is also expressed in macro-
phages in humans and mice. Expression of LOX-1 can be induced
after macrophage-like differentiation in vitro in human periph-
eral blood monocytes and the related cell line THP-1 cells.
Furthermore, LOX-1 expression can also be detected in resident
peritoneal macrophages, and can be upregulated by an inflam-
matory cytokine TNF-K. These results suggest that LOX-1 in
macrophages may play an important role in Ox-LDL uptake and
subsequent foam cell formation in this cell type.
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1. Introduction
Accumulation of cholesterol-loaded foam cells derived from
a monocyte-macrophage lineage in the arterial intima appears
to be a hallmark and a key event in early atherogenesis [1].
Several lines of evidence suggested that oxidatively modi¢ed
low density lipoprotein (Ox-LDL) may play crucial roles in
atherogenesis. Ox-LDL can be avidly taken up by macro-
phages by receptor-mediated endocytosis, which subsequently
transform them into foam cells [2^4]. Several di¡erent mole-
cules, such as class A macrophage scavenger receptors [5,6],
MARCO [7], Fc-Q RII [8], CD36 [9], scavenger receptor class
B type I (SR-BI) [10] and CD68 (macrosialin) [11], have been
identi¢ed as cell-surface receptors for atherogenic Ox-LDL;
however, additional molecules speci¢c for Ox-LDL may also
be involved in Ox-LDL uptake and subsequent foam cell
transformation in macrophages [12^15].
Recent studies in our laboratory have identi¢ed a novel
class of Ox-LDL receptor, which has been designated lectin-
like Ox-LDL receptor-1 (LOX-1) in vascular endothelial cells
[16]. LOX-1 is a type II membrane glycoprotein with approx-
imate molecular mass of 50 kDa. LOX-1 can bind, internalize,
and proteolytically degrade Ox-LDL, but not signi¢cant
amounts of acetylated LDL [17]. Expression of LOX-1 can
be upregulated by tumor necrosis factor K (TNF-K), phorbol
12-myristate 13-acetate (PMA), and £uid shear stress, suggest-
ing that LOX-1 expression in vivo in vascular endothelium
may also be dynamically regulated by in£ammatory and £uid
mechanical stimuli [18,19].
In the present study, we explored whether LOX-1, a novel
receptor for Ox-LDL identi¢ed in vascular endothelial cells, is
also expressed in macrophages.
2. Materials and methods
2.1. Materials
RPMI-1640 medium and DMEM medium were obtained from Nis-
sui, Japan. Fetal bovine serum (FBS) was purchased from Irvine
Scienti¢c, Santa Ana, CA. PMA was obtained from Sigma. Recombi-
nant human TNF-K was purchased from Boehringer Mannheim.
Mouse anti-bovine LOX-1 monoclonal antibody 5-2 (mAb 5-2; hy-
bridoma supernatants) was prepared by immunization with a re-
combinant bovine LOX-1 extracellular domain produced by Esche-
richia coli as previously described. Rabbit anti-mouse LOX-1
polyclonal antibody (2-1) was prepared by immunization with syn-
thetic peptides of mouse LOX-1 extracellular domain (amino acids
237^257). Murine anti-human CD68 monoclonal antibody (KP1)
was purchased from Dako. Non-immune mouse IgG fraction was
obtained from Funakoshi, Japan.
2.2. Cells
Human peripheral blood mononuclear cells were freshly isolated
from blood of healthy volunteers by Ficoll density gradient centrifu-
gation (Lymphoprep, Nycomed Pharma AS, Oslo, Norway), as well
as bu¡y coats kindly provided by the Kyoto Red Cross Blood Center.
Mononuclear cells were suspended in RPMI 1640 supplemented with
20% (v/v) autologous human serum. After 3 h of incubation, non-
adherent cells were removed by washing with phosphate-bu¡ered sal-
ine (PBS, 150 mM Nacl, 10 mM phosphate bu¡er, pH 7.4). Adherent
cells were cultured as monocytes until used for experiments. Human
monocytic cell line THP-1 cells were cultured in RPMI 1640 supple-
mented with 10% FBS. THP-1 cells were di¡erentiated into adherent
macrophages by treatment with 3^30U1038 M PMA for 3^4 days
[20]. Mouse peritoneal macrophages were harvested from peritoneal
lavage of female DDY mice which had been injected intraperitoneally
with 2 ml of 3% thioglycollate broth (Difco) in PBS. Cells were sus-
pended in DMEM containing 10% FBS at a density of 3U106 cells/ml
and allowed to adhere for 3 h incubation. The cells were then washed
with PBS to remove non-adherent cells and incubated overnight.
2.3. Northern blot analysis
10 Wg of total cellular RNA extracted from cells using RNAzol B
(Tel-Test, Friendswood, TX) was fractionated in formaldehyde-agar-
ose (1.2%) gels and transferred onto maximum strength Nylon mem-
branes (Schleicher and Schuell, Keene, NH). Membranes were hybrid-
ized with a 0.8 kb EcoRI fragment of human LOX-1 cDNA or a 0.8
kb BamHI-HindIII fragment of mouse LOX-1 cDNA which had been
labeled with [K-32P]dCTP (Dupont-New England Nuclear) by random
hexanuclide primers (DNA labeling Kit; Pharmacia). Blots were sub-
sequently hybridized with radiolabeled human glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) cDNA to control amounts of RNA
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loaded. Intensities of bands were quanti¢ed by BAS 2000 image an-
alyser (Fuji Film, Japan)
2.4. Immunocytochemistry
Cells cultured in chamber slides were ¢xed with acetone/methanol
(1:1) at 320‡C for 5 min. After incubation with 0.1% BSA-PBS con-
taining 2% horse serum for 30 min, cells were incubated with an anti-
LOX-1 monoclonal antibody, an anti-human CD68 monoclonal anti-
body or non-immune mouse IgG for 20 min. Concentrations of the
primary antibodies were optimized by preliminary experiments. After
washing with 0.1% BSA-PBS three times, cells were incubated with
biotinylated secondary antibodies (horse anti-mouse IgG) for 30 min
and washed with 0.1% BSA-PBS twice and with PBS once. Endoge-
nous peroxidase activity was then blocked by incubation with meth-
anol containing 0.3% hydrogen peroxide for 30 min, after which avi-
din-biotin peroxidase complexes (ABC Elite kit, Vector Labs,
Burlingame, CA) were added. Antibody binding was visualized by
3,3P-diaminobenzidine tetrahydrochloride (DAB substrate kit, Vector
Labs, Burlingame CA), and cells were then counterstained with Gill’s
hematoxylin.
2.5. Immunoblot analysis
Scraped cells were lysed in homogenization solution (20 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1 mM PMSF, 1 Wg/ml
leupeptin, 1 mM aprotinin), and lysates were passed through 26-gauge
needles 10 times. To prepare solubilized membrane proteins, lysates
were centrifuged at 50 000 rpm at Beckman TLA 100.3 rotor for 30
min at 4‡C. A ¢fth volume of 5USDS sample bu¡er (0.25 M Tris-
HCl, pH 6.8, 4% SDS, 10% glycerol, 0.02% bromophenol blue) was
added to the supernatants. After heating at 98‡C for 5 min, samples
were subjected to SDS-polyacrylamide gels (10% or 4^20% gradients)
electrophoresis and electrotransferred onto PVDF membranes (Poly-
Screen, Dupont) using a semidry electrotransfer apparatus (Bio-Rad).
After blocking non-speci¢c binding with milk for 2 h, membranes
were rinsed with TBS/0.1% Tween 20, incubated with anti-mouse
LOX-1 polyclonal Ab 2-1 at a 1:500 dilution for 2 h and then washed
three times. Protein-antibody complexes were detected using the En-
hanced Chemiluminescence kit (Amersham). Protein concentration
was determined with the Bradford reagent (BRL).
3. Results and discussion
Accumulation of macrophage-derived foam cells in arterial
intima appears to be a hallmark of early atherogenesis.
Although previous studies by several investigators have iden-
ti¢ed several molecules as receptors for Ox-LDL in macro-
phages, additional molecules may also been involved in
foam cell transformation in this cell type. LOX-1 is a cell
surface molecules identi¢ed as a receptor for Ox-LDL in vas-
cular endothelial cells. In the present study, therefore, we
sought to de¢ne to whether LOX-1 is also expressed in macro-
phages.
The human monocytic cell line THP-1 has been shown to
be di¡erentiated into macrophage-like cells after treatment
with PMA [20,21]. Therefore, THP-1 cells were treated with
PMA (30 nM) for the indicated time periods, and Northern
blotting was performed to evaluate LOX-1 mRNA expression.
As shown in Fig. 1A, LOX-1 mRNA was not detectable in
untreated THP-1 cells. In PMA-treated THP-1 cells, in con-
trast, LOX-1 mRNA expression was time-dependently in-
duced. LOX-1 mRNA was detectable as early as 12 h after
PMA treatment, and remained expressed for at least 7 days.
Fig. 1B shows concentration dependence in PMA-induced
LOX-1 expression. PMA concentrations as low as 10 nM
can induce expression of LOX-1 mRNA after 3 days (Fig.
1B). These results appear to be in parallel to the previous
report which showed time- and concentration-dependent in-
duction of class A scavenger receptors in PMA-treated THP-1
cells [20].
We further explored expression of LOX-1 mRNA in human
monocyte-derived macrophages. Human peripheral blood
monocytes were di¡erentiated into macrophages after in vitro
culture for several days, and Northern blot analysis was per-
formed [22]. As shown in Fig. 2, signi¢cant expression of
LOX-1 mRNA was found in these monocyte-derived macro-
phages. In freshly isolated human peripheral monocytes be-
fore cell culture LOX-1 mRNA expression was not detectable
by RT-PCR analysis (data not shown). These results appear
to be in parallel with those found in THP-1 cells.
To examine whether LOX-1 protein is also expressed in
macrophages, immunocytochemistry using an anti-LOX-1
antibody was carried out. THP-1 cells were subjected to mac-
rophage-like di¡erentiation by PMA treatment for 3 days.
Human monocyte-derived macrophages were obtained after
in vitro cell culture for 10 days. In these cells that had under-
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Fig. 1. Expression of LOX-1 mRNA during di¡erentiation of THP-
1 cells by PMA. THP-1 cells were cultured in RPMI 1640 supple-
mented with 10% FBS in the presence of PMA. A: After incubation
with 30 nM PMA for 12 h, 1, 3, 5, or 7 days, total RNA was iso-
lated and subjected to Northern blot analysis. B: After incubation
with the indicated concentrations of PMA for 3 days, total RNA
was isolated and subjected to Northern blot analysis.
Fig. 2. Expression of LOX-1 mRNA in human monocyte-derived
macrophages. Human peripheral blood monocytes were di¡erenti-
ated into macrophages by culturing in RPMI 1640 containing 20%
autologous serum for the indicated time periods. Total cellular
RNA was isolated on days 5, 7, 9, 11 and subsequently subjected to
Northern blot analysis.
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gone macrophage-like di¡erentiation, signi¢cant expression of
LOX-1 as well as CD68, a marker for macrophages, was
observed by immunostaining (Fig. 3).
In addition, murine peritoneal macrophages were harvested
by peritoneal lavage, and expression of LOX-1 was evaluated.
As shown in Fig. 4, expression of LOX-1 mRNA was detect-
able in murine peritoneal macrophages. Treatment with the
in£ammatory cytokine TNF-K signi¢cantly upregulated ex-
pression of LOX-1 mRNA in a time- and concentration-de-
pendent manner. The upregulation of LOX-1 expression ap-
pears to be in parallel with our previous ¢ndings that LOX-1
expression can be upregulated by TNF-K in cultured vascular
endothelial cells [18]. Immunoblot analysis also provided evi-
dence that LOX-1 protein is similarly induced by TNF-K
treatment for 24 h (Fig. 5).
Uptake of Ox-LDL in macrophages and subsequent foam
cell transformation appear to play key roles in atherogenesis.
The present study provides evidence that LOX-1, a novel
receptor for Ox-LDL which was originally identi¢ed in vas-
cular endothelial cells, is also expressed in macrophages. Ex-
pression of LOX-1 in macrophages is also upregulated by the
in£ammatory cytokine TNF-K. Interestingly, expression of
class A scavenger receptors has been shown to be downregu-
lated by TNF-K in macrophages [23,24]. Since production of
TNF-K in atherosclerotic lesions has been reported, LOX-1
may play more important roles in atherosclerotic lesions with
in£ammatory responses [25^27].
Our previous report has also shown that LOX-1 can sup-
port binding and engulfment of aged red blood cells and
apoptotic cells [28]. LOX-1 in macrophages, therefore, may
play important roles in the removal of these deteriorated cells.
In summary, this report provides evidence that LOX-1 is
expressed in macrophages and upregulated by an in£amma-
tory stimulus. Further studies relating to pathophysiological
roles of LOX-1 in macrophages and other cell types in vivo
may provide new insights into atherogenesis as well as in£am-
matory diseases.
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